1
|
Ruiz MG, Pardo J, Cruellas M, Esteban P, Galvez E, Lastra R, Martinez-Lostao L, Ocariz M, Paño J, Quilez E, Ramirez A, Sesma A, Torres-Ramón I, Yubero A, Zapata M, Isla D. EP16.01-014 Characterisation of Circulating Immune Cells in a Cohort of Non-small Cell Lung Cancer Patients Treated with Immunotherapy. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.1014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
2
|
de Juan A, Redondo A, Rubio MJ, García Y, Cueva J, Gaba L, Yubero A, Alarcón J, Maximiano C, Oaknin A. SEOM clinical guidelines for cervical cancer (2019). Clin Transl Oncol 2020; 22:270-278. [PMID: 31981078 DOI: 10.1007/s12094-019-02271-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Accepted: 12/10/2019] [Indexed: 01/02/2023]
Abstract
Cervical cancer (CC) is the fourth most common cancer in women worldwide, strongly linked to high-risk human papilloma virus infection. In high-income countries, the screening programs have dramatically decreased the incidence of CC; however, the lack of accessibility to them in developing countries makes CC an important cause of mortality. Clinical stage is the most relevant prognostic factor in CC. The new FIGO staging system published in 2018 is more accurate than the previous one since it takes into account the lymph node status. In early stages, the primary treatment is surgery-with some concerns recently raised regarding minimally invasive surgery because it might decrease survival-or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stages. For recurrent or metastatic CC, the combination of chemotherapy plus bevacizumab is the preferred therapy. Immunotherapy approach based on checkpoint inhibitors is evolving as the election therapy following failure to platinum therapy.
Collapse
Affiliation(s)
- A de Juan
- Medical Oncology Department, H. Universitario Marqués de Valdecilla, Santander, Spain
| | - A Redondo
- Medical Oncology Department, H. Universitario La Paz, Madrid, Spain
| | - M J Rubio
- Medical Oncology Department, H. Universitario Reina Sofía, Córdoba, Spain
| | - Y García
- Medical Oncology Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain, Sabadell, Spain
| | - J Cueva
- Medical Oncology Department, Complejo Hospitalario Universitario de Santiago, Santiago, Spain
| | - L Gaba
- Medical Oncology Department, H. Clinic i Provincial de Barcelona, Barcelona, Spain
| | - A Yubero
- Medical Oncology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - J Alarcón
- Medical Oncology Department, H. Universitari Son Espases, Palma de Mallorca, Spain
| | - C Maximiano
- Medical Oncology Department, H. Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | - A Oaknin
- Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
| |
Collapse
|
3
|
Cubero JL, Escudero P, Yubero A, Millán P, Sagredo MA, Colás C. Successful Desensitization to Irinotecan After Severe Hypersensitivity Reaction. J Investig Allergol Clin Immunol 2016; 26:314-316. [DOI: 10.18176/jiaci.0075] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Serrano S, Martinez-Trufero J, Miguelsanz S, Yubero A, Lastra R, Polo E, Lambea J, Seguí M, Pujol E, Isla D. 8520 Preliminary results of a pilot study with a modified induction docetaxel/cisplatin/5-FU (TPF) followed by concomitant chemoradiotherapy (CT/RT) in locally advanced head and neck cancer (LAHNC). EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71611-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
5
|
Isla D, Martínez-Trufero J, Morales S, Yubero A, Lambea J, Álvarez I, Polo E, Seguí MA, Pujol E, Pastor P. A pilot study of modified neoadjuvant docetaxel/cisplatin/5-FU (TPF) to concomitant chemoradiotherapy (CT/RT) in locally advanced head and neck cancer (LAHNC): Preliminary results. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.6039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6039 Background: Sequential treatment with induction CT followed by CT/RT is highly active and under study in ongoing randomized trials. We started a pilot phase II trial to explore the efficacy, toxicity profile and organ preservation of a modified neoadjuvant TPF to concurrent CT/RT in both resectable (R) and unresectable (UR) LAHNC. Methods: One hundred seventy patients(p) with stage III-IV, PS ECOG 0–2, were included to receive 3 cycles of docetaxel 75 mg/m2 iv day(d) 1, cisplatin(P) 75 mg/m2 iv d2 and 5-FU 750 mg/m2 iv continuous infusion d2–5, every 3 weeks with prophylactic ciprofloxacin 500 mg twice daily from d6–15 of each cycle and granulocyte colony-stimulating factor as secondary or primary setting, followed by P 100 mg/m2 iv d1, 22, 43 concomitant with RT (66–70 Gy, conventional fractionation). Neck dissection was planned for p with stage N2–3 after induction CT or salvage surgery for resectable p with persistent disease at the end of treatment. Results: Main p characteristics were: median age 58 years (39–77), male 89%, ECOG 0/1/2 47%/50.6%/2.4%, stage IV 62.7%, larynx/hipopharynx/oral cavity/oropharynx 45%/12%/17.3%/25.7% and R/UR 41.8%/58.2%. Median TPF/P cycles administered were 3/3. Neoadjuvant CT/total treatment overall response rate evaluation (R/UR): 70% (73%/68%)/86% (84%/88%). Neck dissection was performed in 16 p and salvage surgery in 6 p. Organ preservation was achieved in 90.8% of R p. Main G3–4 toxicity during TPF treatment was neutropenia 11.2%, febrile neutropenia 11.2%, mucositis 11.2%, and during CT/RT mucositis 16.5%, neutropenia 16.5%. Median time to progression was 19.5 m(R:15.6, UR:20.3), and median overall survival was not reached (R:not reached, UR:32.8). Conclusions: Preliminary results indicate that modified neoadjuvant TPF followed by CT/RT is an active and well tolerated regimen in LAHNC, with satisfactory organ preservation and survival. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Isla
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - J. Martínez-Trufero
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - S. Morales
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - A. Yubero
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - J. Lambea
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - I. Álvarez
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - E. Polo
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - M. A. Seguí
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - E. Pujol
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - P. Pastor
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| |
Collapse
|
6
|
Lorenzo A, Modolell A, Valero P, Murillo L, García-Bueno JM, Yubero A, Machengs I. Docetaxel and carboplatin followed by sequential capecitabine as first line treatment in patients with locally advanced or metastatic breast cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-2155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #2155
Background: Anthracyclines and docetaxel (D) are the most active agents in metastatic breast cancer (BC). New regimens are being assesed to improve chemotherapy efficacy. D and carboplatin (C) has shown to be an active treatment in metastatic BC. Capecitabine (X) and D is also an active combination, despite the fact the toxicity profile needs to be improved. Sequential administration of D and X could lead to an improved toxicity profile compared with concomitant administration. We designed this study to evaluate activity and toxicity profile of treatment with D and C followed by sequential X in patients with locally advanced or metastatic BC.
 Methods: Patients with locally advanced or metastatic BC, at least one measurable lesion, age ≥ 18 years, ECOG PS ≤ 2, and adequate bone marrow and hepatic functions, were included in the study. Prior chemotherapy or radiotherapy for advanced disease was not allowed. Patients received 6 cycles of D 75 mg/m2 iv D1 and C AUC5 iv D1, every 21 days followed by 12 cycles of X 2000 mg/m2/day o.r. D1-14 in a 21 days course.
 Results: twenty patients have been analyzed. Median age was 55 years old (range 36-73), ECOG PS 0-1 94.4%; 90.0% of patients had infiltrating ductal carcinoma and 57.9% of patients had stage I-II at diagnosis. Main sites of metastatic disease were bone (35.0%), liver (25.0%) and lung (25.0%). Conservative surgery was performed in 35% of patients and mastectomy in 40%. Previous radiotherapy and chemotherapy was administered in 50.0% and 70.0% of patients, respectively. A total of 108 cycles of D and C (median 6, range 2-6) and 71 cycles of X (median 6, range 2-10) were administered. Median relative dose intensity was 96% for D and C and 95% for X. Over 17 evaluable patients for efficacy, 2 achieved complete response and 4 partial response; the ORR was 35.3% (95% CI:12.6-58.1). During D and C treatment, grade III/IV toxicities per patient were neutropenia (25.0%), leucopenia (10.0%), mucositis (5.0%), oedema (5.0%), febrile neutropenia (5.0%) and thrombophlebitis (5.0%). Most common grade II toxicities were nausea (20.0%), vomiting (15.0%) and asthenia (20.0%). During X treatment, grade III/IV toxicities per patient were neutropenia (7.1%) and hand-foot syndrome (7.1%). Main grade II toxicity was hand-foot syndrome (14.3%). Two patients finished treatment after 2 and 6 cycles of X due to diarrhea, oedema and anorexia, and hand-foot syndrome.
 Conclusion: In this preliminary analysis, D and C followed by sequential X seems to be an active and well-tolerated regimen as first line treatment in patients with locally advanced or metastatic BC.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2155.
Collapse
Affiliation(s)
- A Lorenzo
- 1 Servicio Oncología Médica, H. Universitario de Puerto Real, Cádiz, Spain
| | - A Modolell
- 2 Instituto de Oncología Corachán, Barcelona, Spain
| | - P Valero
- 3 Servicio Oncología Médica, Clínica Infanta Luisa, Sevilla, Spain
| | - L Murillo
- 4 Servicio Oncología Médica, H. Reina Sofía de Tudela, Navarra, Spain
| | - JM García-Bueno
- 5 Servicio Oncología Médica, Policlínica Miramar, Palma de Mallorca, Spain
| | - A Yubero
- 6 Servicio Oncología Médica, H. Obispo Polanco, Teruel, Spain
| | - I Machengs
- 7 Servicio Oncología Médica, H. Sagrat Cor, Barcelona, Spain
| |
Collapse
|
7
|
Mayordomo JI, Lorenzo A, Modolell A, Alvarez I, Bayo J, Machengs-M Centelles-K Villadiego I, Rubio MJ, Heras L, Yubero A, Gonzálvez ML, Valero J. A multicenter pilot study of adjuvant docetaxel, epirubicin and cyclophosphamide (TEC) in patients (p) with stage II/III and node-positive breast cancer (BC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11029 Background: Based on wide experience with docetaxel, adriamicin and cyclophosphamide (TAC regimen) for adjuvant therapy of node-positive BC but taking into account the high incidence of febrile neutropenia and mucositis, we performed the present study with TEC aiming for a better toxicity profile at doses equipotent to TAC. Methods: 300 p with histological diagnosis of stage II-III BC, positive axillary lymph nodes, age 18 year old, ECOG PS 0–2 and adequate bone marrow, renal, hepatic and cardiac function were accrued after surgery. Prior chemotherapy, hormone therapy and radiotherapy for BC were not allowed. Treatment: T 75 mg/m2 iv d1, E 75 mg/m2 iv d1 and C 500 mg/m2 iv d1 every 21 days for 6 cycles. G-CSF 5 mcg/Kg /day s.c. was given on days 5 to 9. Results: Two hundred and one p having completed adjuvant therapy have been evaluated in this interim analysis. Median age: 53 years (range 25–77), ECOG PS 0/1 89%/11%, infiltrating ductal carcinoma 77%. Hormone receptor status was ER+ 79% and PR+ 60%. Surgery was mastectomy in 49% and conservative surgery in 51% of pts. Median number of positive axillary lymph nodes was 3. To date, 1,085 cycles were administered (median 6). Median relative dose intensity was 99% for T and 98% for E and C. There were 11 dose reductions for non- hematological toxicity and 4 for hematological toxicity. Toxicity: grade 3–4 neutropenia occurred in 15 p (7.5%), 8 of them were episodes of febrile neutropenia (4.0%). Other grade 3–4 toxicities per p were: leukopenia (7.0%), thrombocytopenia (0.5%), asthenia (6.5%), vomiting (4.5%), nausea (3.5%) and diarrhoea (3.0%). Four p (2.0%) discontinued therapy due to toxicity: 1 p with toxicodermic reaction, 1 p with hematological toxicity, 1 p with febrile neutropenia and 1 p with an allergic reaction to T. After study treatment, radiotherapy was administered to 63% of p and hormonotherapy to 66% of p. Conclusions: These preliminary results show that adjuvant TEC in p with stage II/III BC and positive axillary lymph nodes is feasible and well tolerated. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. I. Mayordomo
- Hospital Clinico Universitario, Zaragoza, Spain; Hospital Universitario de Puerto Real, Puerto Real (Cádiz), Spain; Instituto de Oncología Corachán, Barcelona, Spain; Hospital General San Jorge, Huesca, Spain; Hospital Juan Ramón Jiménez, Huelva, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital de la Cruz Roja, Córdoba, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital de la Arritxaca, Murcia, Spain; Clínica Infanta Luisa, Sevilla, Spain
| | - A. Lorenzo
- Hospital Clinico Universitario, Zaragoza, Spain; Hospital Universitario de Puerto Real, Puerto Real (Cádiz), Spain; Instituto de Oncología Corachán, Barcelona, Spain; Hospital General San Jorge, Huesca, Spain; Hospital Juan Ramón Jiménez, Huelva, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital de la Cruz Roja, Córdoba, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital de la Arritxaca, Murcia, Spain; Clínica Infanta Luisa, Sevilla, Spain
| | - A. Modolell
- Hospital Clinico Universitario, Zaragoza, Spain; Hospital Universitario de Puerto Real, Puerto Real (Cádiz), Spain; Instituto de Oncología Corachán, Barcelona, Spain; Hospital General San Jorge, Huesca, Spain; Hospital Juan Ramón Jiménez, Huelva, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital de la Cruz Roja, Córdoba, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital de la Arritxaca, Murcia, Spain; Clínica Infanta Luisa, Sevilla, Spain
| | - I. Alvarez
- Hospital Clinico Universitario, Zaragoza, Spain; Hospital Universitario de Puerto Real, Puerto Real (Cádiz), Spain; Instituto de Oncología Corachán, Barcelona, Spain; Hospital General San Jorge, Huesca, Spain; Hospital Juan Ramón Jiménez, Huelva, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital de la Cruz Roja, Córdoba, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital de la Arritxaca, Murcia, Spain; Clínica Infanta Luisa, Sevilla, Spain
| | - J. Bayo
- Hospital Clinico Universitario, Zaragoza, Spain; Hospital Universitario de Puerto Real, Puerto Real (Cádiz), Spain; Instituto de Oncología Corachán, Barcelona, Spain; Hospital General San Jorge, Huesca, Spain; Hospital Juan Ramón Jiménez, Huelva, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital de la Cruz Roja, Córdoba, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital de la Arritxaca, Murcia, Spain; Clínica Infanta Luisa, Sevilla, Spain
| | - I. Machengs-M Centelles-K Villadiego
- Hospital Clinico Universitario, Zaragoza, Spain; Hospital Universitario de Puerto Real, Puerto Real (Cádiz), Spain; Instituto de Oncología Corachán, Barcelona, Spain; Hospital General San Jorge, Huesca, Spain; Hospital Juan Ramón Jiménez, Huelva, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital de la Cruz Roja, Córdoba, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital de la Arritxaca, Murcia, Spain; Clínica Infanta Luisa, Sevilla, Spain
| | - M. J. Rubio
- Hospital Clinico Universitario, Zaragoza, Spain; Hospital Universitario de Puerto Real, Puerto Real (Cádiz), Spain; Instituto de Oncología Corachán, Barcelona, Spain; Hospital General San Jorge, Huesca, Spain; Hospital Juan Ramón Jiménez, Huelva, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital de la Cruz Roja, Córdoba, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital de la Arritxaca, Murcia, Spain; Clínica Infanta Luisa, Sevilla, Spain
| | - L. Heras
- Hospital Clinico Universitario, Zaragoza, Spain; Hospital Universitario de Puerto Real, Puerto Real (Cádiz), Spain; Instituto de Oncología Corachán, Barcelona, Spain; Hospital General San Jorge, Huesca, Spain; Hospital Juan Ramón Jiménez, Huelva, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital de la Cruz Roja, Córdoba, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital de la Arritxaca, Murcia, Spain; Clínica Infanta Luisa, Sevilla, Spain
| | - A. Yubero
- Hospital Clinico Universitario, Zaragoza, Spain; Hospital Universitario de Puerto Real, Puerto Real (Cádiz), Spain; Instituto de Oncología Corachán, Barcelona, Spain; Hospital General San Jorge, Huesca, Spain; Hospital Juan Ramón Jiménez, Huelva, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital de la Cruz Roja, Córdoba, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital de la Arritxaca, Murcia, Spain; Clínica Infanta Luisa, Sevilla, Spain
| | - M. L. Gonzálvez
- Hospital Clinico Universitario, Zaragoza, Spain; Hospital Universitario de Puerto Real, Puerto Real (Cádiz), Spain; Instituto de Oncología Corachán, Barcelona, Spain; Hospital General San Jorge, Huesca, Spain; Hospital Juan Ramón Jiménez, Huelva, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital de la Cruz Roja, Córdoba, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital de la Arritxaca, Murcia, Spain; Clínica Infanta Luisa, Sevilla, Spain
| | - J. Valero
- Hospital Clinico Universitario, Zaragoza, Spain; Hospital Universitario de Puerto Real, Puerto Real (Cádiz), Spain; Instituto de Oncología Corachán, Barcelona, Spain; Hospital General San Jorge, Huesca, Spain; Hospital Juan Ramón Jiménez, Huelva, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital de la Cruz Roja, Córdoba, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital de la Arritxaca, Murcia, Spain; Clínica Infanta Luisa, Sevilla, Spain
| |
Collapse
|
8
|
Maestu I, Muñoz J, Gómez-Aldaraví L, Esquerdo G, Yubero A, Torregrosa MD, Romero R. Assessment of functional status, symptoms and comorbidity in elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine and vinorelbine. Clin Transl Oncol 2007; 9:99-105. [PMID: 17329221 DOI: 10.1007/s12094-007-0019-2] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
BACKGROUND The incidence and prevalence of comorbid conditions in lung cancer patients increase with age. The aim of the study was to determine response and tolerability with the biweekly combination gemcitabine-vinorelbine in elderly non-small-cell lung cancer (NSCLC) patients. In order to characterise the population included in the study well and assess the results achieved properly, an evaluation of the functional status, comorbidity and survival was performed. PATIENTS AND METHOD Between June 2001, and December 2003, 59 untreated advanced NSCLC patients over the age of 70 years entered the study. Treatment consisted of gemcitabine 1750 mg/m(2) and vinorelbine 30 mg/m(2) on day 1 every two weeks. The response was evaluated every f ive cycles (RECIST guidelines). Comorbidity was evaluated according to the Charlson and Kaplan Feinstein scales. To measure functional status, activities of daily living (ADL) and instrumental ADL (IADL) were considered. RESULTS Median age was 74; ECOG performance status was >2 in 59.3%; no dependence in ADL or IADL was found in 24.8% and 42.4% of patients, respectively. A total of 381 courses were administered. Grade 3-4 neutropenia was present in 6.8% of these courses and correlated with IADL. Objective response was 22% (95% CI 12-32). Mean global survival and cause-specific survival were 29 weeks (95% CI 19.9-38.1) and 32 weeks (95% CI 23.4-40.8) respectively. Comorbidity displayed no close correlation with functional status, but comorbidity according to the Kaplan Feinstein index correlated with IADL. Performance status, ADL, IADL and weight loss were significantly related to survival in multivariate analysis. CONCLUSIONS This biweekly combination is feasible in elderly lung cancer patients with a high burden of comorbidity and dependence. Toxicity is acceptable, whereas response rate and survival fall in the range of active regimens. ADL and IADL indices allow the identification of elderly patients with a worse prognosis.
Collapse
Affiliation(s)
- I Maestu
- Oncology Department, Virgen de los Lirios Hospital, Poligono de Caramanxel s/n, 03804 Alcoy, Alicante, Spain.
| | | | | | | | | | | | | |
Collapse
|
9
|
Zamora P, Álvarez de Mon M, Calvo L, Jara C, Virizuela JA, Yubero A, Chacón J, Mira J, González Barón M. Phase II study of capecitabine (X) as single agent in elderly patients (p) with metastatic breast cancer (MBC): Final results. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10709] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10709 Background: X is a selectively tumour-activated fluoropyrimidine active in solid tumours. Twice-daily oral administration of X enables chronic dosing that mimics a continuous infusion of 5-FU. In p with pretreated advanced BC, X is effective as monotherapy and also in combination with other agents. Some studies have shown that safety data of X in general population also apply to elderly p. The objective of this study is to evaluate the toxicity profile and response rate of X in elderly p with MBC. Methods: P histologically confirmed of breast adenocarcinoma, metastatic disease, age ≥70 years, ECOG PS <2, measurable disease and adequate bone marrow, renal and hepatic functions were included. Prior X, CNS metastases or radiotherapy within 4 weeks of treatment start was not allowed. P received X monotherapy 1250 mg/m2 b.i.d. (X 950 mg/m2 in p with creatinine clearance 30–50 ml/min), days 1–14 every 3 weeks for a maximum of 9 cycles. P can be previously treated with chemotherapy, hormonotherapy or radiotherapy for the metastatic disease. Clinical response was evaluated every 3 cycles (RECIST). Results: Twenty three p were enrolled with histology confirmed adenocarcinoma, median age was 77 years old (68–88) and ECOG PS 0/1 in 33%/67% of p. Surgery was performed in all p. Adjuvant chemotherapy and hormonotherapy was administered in 65% and 74% of p, respectively. Prior chemotherapy for MBC was administered in 13.0% of p. Median number of metastatic lesions was 3 (90% with ≥2 sites), in bone (57%), lung (43%), liver (43%) and lymph nodes (38%) mainly. A total of 117 cycles (median 4, range 1–9) were administered. Median RDI was 86% and 100% for X 1250 mg/m2 and X 950 mg/m2, respectively. All p were evaluable for toxicity. Grade III/IV toxicity per patient were hand-foot syndrome (13%), asthenia (13%), mucositis (9%), diarrhoea (9%), neutropenia (4%), thrombocytopenia (4%), nausea (4%) and vomiting (4%). Efficacy analysis: over 16 evaluable p, 2 achieved PR, 7 SD and 7 PD, resulting in an ORR of 13% (95% CI: 0–29). Median TTP was 7.5 months (95% CI: 4.5–10.5), median OS was 13.3 months (95% CI: 9.6–16.9) and one year survival 55.5% (95% CI: 33.7–77.2). Conclusions: Twice daily oral X seems to be an effective and well tolerated treatment in pretreated elderly MBC p. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Zamora
- Hospital La Paz, Madrid, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hospital Juan Canalejo, La Coruña, Spain; Fundación Hospital Alcorcón, Madrid, Spain; Hospital Virgen de la Macarena, Sevilla, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Virgen de la Salud, Toledo, Spain; H.C.R. Noroeste de Murcia, Murcia, Spain
| | - M. Álvarez de Mon
- Hospital La Paz, Madrid, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hospital Juan Canalejo, La Coruña, Spain; Fundación Hospital Alcorcón, Madrid, Spain; Hospital Virgen de la Macarena, Sevilla, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Virgen de la Salud, Toledo, Spain; H.C.R. Noroeste de Murcia, Murcia, Spain
| | - L. Calvo
- Hospital La Paz, Madrid, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hospital Juan Canalejo, La Coruña, Spain; Fundación Hospital Alcorcón, Madrid, Spain; Hospital Virgen de la Macarena, Sevilla, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Virgen de la Salud, Toledo, Spain; H.C.R. Noroeste de Murcia, Murcia, Spain
| | - C. Jara
- Hospital La Paz, Madrid, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hospital Juan Canalejo, La Coruña, Spain; Fundación Hospital Alcorcón, Madrid, Spain; Hospital Virgen de la Macarena, Sevilla, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Virgen de la Salud, Toledo, Spain; H.C.R. Noroeste de Murcia, Murcia, Spain
| | - J. A. Virizuela
- Hospital La Paz, Madrid, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hospital Juan Canalejo, La Coruña, Spain; Fundación Hospital Alcorcón, Madrid, Spain; Hospital Virgen de la Macarena, Sevilla, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Virgen de la Salud, Toledo, Spain; H.C.R. Noroeste de Murcia, Murcia, Spain
| | - A. Yubero
- Hospital La Paz, Madrid, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hospital Juan Canalejo, La Coruña, Spain; Fundación Hospital Alcorcón, Madrid, Spain; Hospital Virgen de la Macarena, Sevilla, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Virgen de la Salud, Toledo, Spain; H.C.R. Noroeste de Murcia, Murcia, Spain
| | - J. Chacón
- Hospital La Paz, Madrid, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hospital Juan Canalejo, La Coruña, Spain; Fundación Hospital Alcorcón, Madrid, Spain; Hospital Virgen de la Macarena, Sevilla, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Virgen de la Salud, Toledo, Spain; H.C.R. Noroeste de Murcia, Murcia, Spain
| | - J. Mira
- Hospital La Paz, Madrid, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hospital Juan Canalejo, La Coruña, Spain; Fundación Hospital Alcorcón, Madrid, Spain; Hospital Virgen de la Macarena, Sevilla, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Virgen de la Salud, Toledo, Spain; H.C.R. Noroeste de Murcia, Murcia, Spain
| | - M. González Barón
- Hospital La Paz, Madrid, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hospital Juan Canalejo, La Coruña, Spain; Fundación Hospital Alcorcón, Madrid, Spain; Hospital Virgen de la Macarena, Sevilla, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Virgen de la Salud, Toledo, Spain; H.C.R. Noroeste de Murcia, Murcia, Spain
| |
Collapse
|
10
|
Modolell A, Mayordomo MD JI, Garcia-Bueno JM, Machengs I, Alvarez I, Centelles M, Palombo H, Burillo M, Yubero A, Murillo L, Andrés R. Multicenter phase II study of liposomal doxorubicin (M) and docetaxel (T) as neoadjuvant treatment in patients with stage II - III breast cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10662] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10662 Background: T and M is a very active chemotherapy regimen for breast cancer. M has been shown to be as effective as doxorubicin at same doses while reducing the cardiotoxicity and causing less myelosuppression. This study was designed to evaluate clinical and pathological response rate (RR) and toxicity after induction chemotherapy in patient with breast cancer. Methods: Patients with histological confirmation of breast cancer (stage II-III and inflammatory), age > 18 years, left ventricular eject fraction > 45% and adequate bone marrow, renal and hepatic function were included in the study. Prior systemic therapy or radiotherapy and surgery for breast cancer were not allowed. Treatment: T (75 mg/m2) iv and M (75 mg/m2) iv, every 21 days during 4 cycles, followed by surgery. Results: To date 59 patients have been enrolled; 50 were included in this interim analysis, with a median age of 52 years old (28–76), ECOG PS 0, 88.0%; ECOG PS 1, 12.0%; breast location: right, 52.0%; peri-postmenopausal status, 44.9%. Positive hormonal receptor status was 63.3%. Histology was ductal carcinoma in 84.0%. Patients received a total of 188 cycles (median 4, range 2–4). Median relative dose intensity was 99% for T and for M. Efficacy: Nine patients were non-evaluable (7 on treatment, 1 consent withdrawal and 1 lost of follow-up). Of 41 evaluable patients, 5 achieved complete response (CR) (12.2%), 26 partial response (PR)(63.4%), 9 stable disease (SD) (22.0%) and 1 progressive disease (PD) (2.4%), resulting in a clinical response rate (RR) of 75.6% (95% CI: 62.5–88.7%). Surgery was performed in 40 patients: six (15.0%) of them had pathological (p) CR, 25 (62.5%) pPR, 9 (22.5%) pSD resulting in a pathological RR of 77.5% (95% CI: 64.6–90.4%). Median of time to progression and overall survival has not been achieved yet. Hematological toxicities grades III/IV per patient were neutropenia (14%), thrombocytopenia (4%), leukopenia (2%), anemia (2%) and febrile neutropenia (12%). Non-hematological grade III/IV toxicities per patient were asthenia (6%), nausea / vomiting (4%) and infection (4%). Conclusions: T and M every 21 days during 4 cycles as induction chemotherapy in stage II and III breast cancer is an active and well tolerated treatment. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Modolell
- Instituto Oncologico Corachan, Barcelona, Spain; Hospital Clinico Universitario, Zaragoza, Spain; Policlinica Miramar, Palma de Mallorca, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Clinica del Remedio, Barcelona, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Reina Sofia, Tudela, Spain
| | - J. I. Mayordomo MD
- Instituto Oncologico Corachan, Barcelona, Spain; Hospital Clinico Universitario, Zaragoza, Spain; Policlinica Miramar, Palma de Mallorca, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Clinica del Remedio, Barcelona, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Reina Sofia, Tudela, Spain
| | - J. M. Garcia-Bueno
- Instituto Oncologico Corachan, Barcelona, Spain; Hospital Clinico Universitario, Zaragoza, Spain; Policlinica Miramar, Palma de Mallorca, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Clinica del Remedio, Barcelona, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Reina Sofia, Tudela, Spain
| | - I. Machengs
- Instituto Oncologico Corachan, Barcelona, Spain; Hospital Clinico Universitario, Zaragoza, Spain; Policlinica Miramar, Palma de Mallorca, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Clinica del Remedio, Barcelona, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Reina Sofia, Tudela, Spain
| | - I. Alvarez
- Instituto Oncologico Corachan, Barcelona, Spain; Hospital Clinico Universitario, Zaragoza, Spain; Policlinica Miramar, Palma de Mallorca, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Clinica del Remedio, Barcelona, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Reina Sofia, Tudela, Spain
| | - M. Centelles
- Instituto Oncologico Corachan, Barcelona, Spain; Hospital Clinico Universitario, Zaragoza, Spain; Policlinica Miramar, Palma de Mallorca, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Clinica del Remedio, Barcelona, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Reina Sofia, Tudela, Spain
| | - H. Palombo
- Instituto Oncologico Corachan, Barcelona, Spain; Hospital Clinico Universitario, Zaragoza, Spain; Policlinica Miramar, Palma de Mallorca, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Clinica del Remedio, Barcelona, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Reina Sofia, Tudela, Spain
| | - M. Burillo
- Instituto Oncologico Corachan, Barcelona, Spain; Hospital Clinico Universitario, Zaragoza, Spain; Policlinica Miramar, Palma de Mallorca, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Clinica del Remedio, Barcelona, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Reina Sofia, Tudela, Spain
| | - A. Yubero
- Instituto Oncologico Corachan, Barcelona, Spain; Hospital Clinico Universitario, Zaragoza, Spain; Policlinica Miramar, Palma de Mallorca, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Clinica del Remedio, Barcelona, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Reina Sofia, Tudela, Spain
| | - L. Murillo
- Instituto Oncologico Corachan, Barcelona, Spain; Hospital Clinico Universitario, Zaragoza, Spain; Policlinica Miramar, Palma de Mallorca, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Clinica del Remedio, Barcelona, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Reina Sofia, Tudela, Spain
| | - R. Andrés
- Instituto Oncologico Corachan, Barcelona, Spain; Hospital Clinico Universitario, Zaragoza, Spain; Policlinica Miramar, Palma de Mallorca, Spain; Hospital Sagrat Cor, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Clinica del Remedio, Barcelona, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Reina Sofia, Tudela, Spain
| |
Collapse
|
11
|
Lastra R, Yubero A, Ortega M, Lambea J, Elena A, Millastre E, Ruiz M, Escudero P, Saenz A, Mayordomo JI, Tres A. Frequency of familiar cancer in a cohort of newly-diagnosed patients with colorectal cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13588 Background: Incidence on Hereditary Non Poliposis Colorectal Cancer (HNPCC) is 3–5% of all colorectal cancers (CRC). Primary identification of patients (p) with high risk of this hereditary syndrome is the first step before genetic testing for MSH2, MLH1 or MSH6 mutations. AIMS: To determine the frequency of family history of CRC in our population Methods: We have assessed cancer history (full family pedigree, including at least 2 generations of ascendants plus all descendants) in a cohort of 100 newly-diagnosed p with CRC cancer seen as first visit at the Division of Medical Oncology of the University Hospital of Zaragoza, Spain, from 2005. We have used the revised Bethesda Guideline for HNPCC published in JNCI (Vol 96. Feb 2004) Results: Median age was 72 (range: 26 - 85). 29 females/71 males. Considering Bethesda criteria for genetic testing, percentages of families fulfilling them were: Cancer before age 50: 7 (7%), synchronous/metachronous cancer: 1 (1%), other HNPCC associated tumors before age 50: 1 (ovarian 1%), One first-degree relative with HPNCC related tumor before age 50: 4 (4%), Two or more family members with HNPCC related cancer: 5 (5%). Overall, 14 (14%) fulfilled at least 1 of these criteria. Number of cases of tumors in the family (for a total of 909 family members) was 82, 10 cases of breast cancer, 23 of colorectal, 6 of gastric, 5 of prostate, 3 gynecologic, 11 lung, and 21 others. Conclusions: Frequency of familiar CC in unselected breast cancer patients of Zaragoza, Spain, is substantially higher than that expected. Assessment of cancer familiar history in the newly-diagnosed patients with CC cancer, helps us to identify families in which a genetic study is to be considered, and this could be useful to prevent new case of cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. Lastra
- Hospital Clínico Universitario de Zaragoza, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Clinico Universitario, Zaragoza, Spain
| | - A. Yubero
- Hospital Clínico Universitario de Zaragoza, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Clinico Universitario, Zaragoza, Spain
| | - M. Ortega
- Hospital Clínico Universitario de Zaragoza, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Clinico Universitario, Zaragoza, Spain
| | - J. Lambea
- Hospital Clínico Universitario de Zaragoza, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Clinico Universitario, Zaragoza, Spain
| | - A. Elena
- Hospital Clínico Universitario de Zaragoza, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Clinico Universitario, Zaragoza, Spain
| | - E. Millastre
- Hospital Clínico Universitario de Zaragoza, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Clinico Universitario, Zaragoza, Spain
| | - M. Ruiz
- Hospital Clínico Universitario de Zaragoza, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Clinico Universitario, Zaragoza, Spain
| | - P. Escudero
- Hospital Clínico Universitario de Zaragoza, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Clinico Universitario, Zaragoza, Spain
| | - A. Saenz
- Hospital Clínico Universitario de Zaragoza, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Clinico Universitario, Zaragoza, Spain
| | - J. I. Mayordomo
- Hospital Clínico Universitario de Zaragoza, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Clinico Universitario, Zaragoza, Spain
| | - A. Tres
- Hospital Clínico Universitario de Zaragoza, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital Clinico Universitario, Zaragoza, Spain
| |
Collapse
|
12
|
Feliu J, Salud A, Escudero P, Lopez-Gómez L, Bolaños M, Galán A, Vicent JM, Yubero A, Losa F, De Castro J, de Mon MA, Casado E, González-Barón M. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006; 94:969-75. [PMID: 16552438 PMCID: PMC2361238 DOI: 10.1038/sj.bjc.6603047] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The purpose of this phase II trial was to determine the efficacy and safety of the XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in the elderly patients with metastatic colorectal cancer (MCRC). A total of 50 patients with MCRC aged > or = 70 years received oxaliplatin 130 mg m(-2) on day 1 followed by oral capecitabine 1000 mg m(-2) twice daily on days 1-14 every 3 weeks. Patients with creatinine clearance 30-50 ml min(-1) received a reduced dose of capecitabine (750 mg m(-2) twice daily). By intent-to-treat analysis, the overall response rate was 36% (95% CI, 28-49%), with three (6%) complete and 15 (30%) partial responses. In total, 18 patients (36%) had stable disease and 14 (28%) progressed. The median times to disease progression and overall survival were 5.8 months (95% CI, 3.9-7.8 months) and 13.2 months (95% CI, 7.6-16.9 months), respectively. Capecitabine was well tolerated: grade 3/4 adverse events were observed in 14 (28%) patients: 11 (22%) diarrhoea, eight (16%) asthenia, seven (14%) nausea/vomiting, three (6%) neutropenia, three (6%) thrombocytopenia, and two (4%) hand-foot syndrome. There was one treatment-related death from diarrhoea and sepsis. In conclusion, XELOX is well tolerated in elderly patients, with respectable efficacy and a meaningful clinical benefit response. Given its ease of administration compared with combinations of oxaliplatin with 5-FU/LV, it represents a good therapeutic option in the elderly.
Collapse
Affiliation(s)
- J Feliu
- Service of Medical Oncology, H La Paz, Universidad Autónoma de Madrid, Paseo de la Castellana 261, Madrid 28046, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Ubieto MA, Abós MD, Tardin AL, Razola P, Prats E, García F, Polo E, Yubero A, Banzo J. [Treatment of bone metastatic pain with Sm153-EDTMP. Evaluation of the analgesic response and the existence of differences according to the primary tumor and the metastatic pattern]. ACTA ACUST UNITED AC 2005; 24:297-304. [PMID: 16194461 DOI: 10.1157/13079280] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
AIMS To evaluate the response to Sm153-EDTMP treatment in patients with metastatic bone pain and the existence of differences in the response according to the scintigraphic pattern (99mTc-MDP) and the primary tumor. MATERIAL AND METHODS We have evaluated the response to Sm153-EDTMP treatment in 32 patients (17 male and 15 female) who received 38 doses (1 mCi/kg). The primary tumor was prostate cancer in 15 patients, breast in 13, lung in 2, intestinal carcinoid in one and unknown in one. Two types of response were considered: a) effective and b) non-effective. Patients were classified into 3 groups according to the metastatic pattern: 1) Superscan (SS), 2) Generalized metastases (GM) and 3) Regional metastases (RM). RESULTS There was effective response in 24 doses (63.15%) and non-effective in 14 (36.84%). The mean duration of the response was 12.08 weeks. Patients with GM pattern showed 16 effective responses (76.19%) and 5 non-effective (23.8%). In SS pattern there were 6 effective responses (60%) and 4 non-effective (40%) and 2 effective (28.57%) and 5 non-effective (71.53%) in RM pattern. These differences did not reach statistical significance (p > 0.05). We did not find differences in the response between prostate cancer (12 effective and 6 non-effective) and breast cancer (10 effective and 6 non-effective) (p = 0.79968). CONCLUSIONS Sm153-EDTMP treatment is efficacious in patients with metastatic bone pain with effective response in 63.15% of the treatments. The response percentage was lower in patients with RM pattern but the differences did not reach statistical significance. There were no differences in the response between prostate and breast cancer patients.
Collapse
Affiliation(s)
- M A Ubieto
- Servicio de Medicina Nuclear, Hospital Clínico Universitario Lozano Blesa, Zaragoza.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Salud A, Escudero P, Feliú J, López-Gómez L, Bolaños M, Galán A, Yubero A, Vicent JM, Losa F, González Barón M. XELOX (capecitabine and oxaliplatin) as 1 st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Salud
- Hosp Arnau de Vilanova, Lleida, Spain; Hosp Lozano Blesa, Zaragoza, Spain; Hosp La Paz, Madrid, Spain; Hosp Virgen de la Salud, Toledo, Spain; Hosp San Pedro de Alcántara, Cáceres, Spain; Hosp de Sagunto, Valencia, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Gen Univ de Valencia, Valencia, Spain; Hosp de la Creu Roja, Barcelona, Spain
| | - P. Escudero
- Hosp Arnau de Vilanova, Lleida, Spain; Hosp Lozano Blesa, Zaragoza, Spain; Hosp La Paz, Madrid, Spain; Hosp Virgen de la Salud, Toledo, Spain; Hosp San Pedro de Alcántara, Cáceres, Spain; Hosp de Sagunto, Valencia, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Gen Univ de Valencia, Valencia, Spain; Hosp de la Creu Roja, Barcelona, Spain
| | - J. Feliú
- Hosp Arnau de Vilanova, Lleida, Spain; Hosp Lozano Blesa, Zaragoza, Spain; Hosp La Paz, Madrid, Spain; Hosp Virgen de la Salud, Toledo, Spain; Hosp San Pedro de Alcántara, Cáceres, Spain; Hosp de Sagunto, Valencia, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Gen Univ de Valencia, Valencia, Spain; Hosp de la Creu Roja, Barcelona, Spain
| | - L. López-Gómez
- Hosp Arnau de Vilanova, Lleida, Spain; Hosp Lozano Blesa, Zaragoza, Spain; Hosp La Paz, Madrid, Spain; Hosp Virgen de la Salud, Toledo, Spain; Hosp San Pedro de Alcántara, Cáceres, Spain; Hosp de Sagunto, Valencia, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Gen Univ de Valencia, Valencia, Spain; Hosp de la Creu Roja, Barcelona, Spain
| | - M. Bolaños
- Hosp Arnau de Vilanova, Lleida, Spain; Hosp Lozano Blesa, Zaragoza, Spain; Hosp La Paz, Madrid, Spain; Hosp Virgen de la Salud, Toledo, Spain; Hosp San Pedro de Alcántara, Cáceres, Spain; Hosp de Sagunto, Valencia, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Gen Univ de Valencia, Valencia, Spain; Hosp de la Creu Roja, Barcelona, Spain
| | - A. Galán
- Hosp Arnau de Vilanova, Lleida, Spain; Hosp Lozano Blesa, Zaragoza, Spain; Hosp La Paz, Madrid, Spain; Hosp Virgen de la Salud, Toledo, Spain; Hosp San Pedro de Alcántara, Cáceres, Spain; Hosp de Sagunto, Valencia, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Gen Univ de Valencia, Valencia, Spain; Hosp de la Creu Roja, Barcelona, Spain
| | - A. Yubero
- Hosp Arnau de Vilanova, Lleida, Spain; Hosp Lozano Blesa, Zaragoza, Spain; Hosp La Paz, Madrid, Spain; Hosp Virgen de la Salud, Toledo, Spain; Hosp San Pedro de Alcántara, Cáceres, Spain; Hosp de Sagunto, Valencia, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Gen Univ de Valencia, Valencia, Spain; Hosp de la Creu Roja, Barcelona, Spain
| | - J. M. Vicent
- Hosp Arnau de Vilanova, Lleida, Spain; Hosp Lozano Blesa, Zaragoza, Spain; Hosp La Paz, Madrid, Spain; Hosp Virgen de la Salud, Toledo, Spain; Hosp San Pedro de Alcántara, Cáceres, Spain; Hosp de Sagunto, Valencia, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Gen Univ de Valencia, Valencia, Spain; Hosp de la Creu Roja, Barcelona, Spain
| | - F. Losa
- Hosp Arnau de Vilanova, Lleida, Spain; Hosp Lozano Blesa, Zaragoza, Spain; Hosp La Paz, Madrid, Spain; Hosp Virgen de la Salud, Toledo, Spain; Hosp San Pedro de Alcántara, Cáceres, Spain; Hosp de Sagunto, Valencia, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Gen Univ de Valencia, Valencia, Spain; Hosp de la Creu Roja, Barcelona, Spain
| | - M. González Barón
- Hosp Arnau de Vilanova, Lleida, Spain; Hosp Lozano Blesa, Zaragoza, Spain; Hosp La Paz, Madrid, Spain; Hosp Virgen de la Salud, Toledo, Spain; Hosp San Pedro de Alcántara, Cáceres, Spain; Hosp de Sagunto, Valencia, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Gen Univ de Valencia, Valencia, Spain; Hosp de la Creu Roja, Barcelona, Spain
| |
Collapse
|
15
|
Zamora P, Álvarez de Mon M, Calvo L, Jara C, Virizuela JA, Yubero A, Chacón JI, Mira J, González Barón M. Capecitabine (X) as single agent in elderly patients (p) with metastatic breast cancer (MBC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.843] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. Zamora
- Hosp La Paz, Madrid, Spain; Hosp Univ Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hosp Juan Canalejo, A Coruña, Spain; Fundación Hosp de Alcorcón, Madrid, Spain; Hosp Univ Virgen de la Macarena, Sevilla, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Virgen de la Salud, Toledo, Spain; H. C. R. Noroeste de Murcia, Murcia, Spain
| | - M. Álvarez de Mon
- Hosp La Paz, Madrid, Spain; Hosp Univ Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hosp Juan Canalejo, A Coruña, Spain; Fundación Hosp de Alcorcón, Madrid, Spain; Hosp Univ Virgen de la Macarena, Sevilla, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Virgen de la Salud, Toledo, Spain; H. C. R. Noroeste de Murcia, Murcia, Spain
| | - L. Calvo
- Hosp La Paz, Madrid, Spain; Hosp Univ Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hosp Juan Canalejo, A Coruña, Spain; Fundación Hosp de Alcorcón, Madrid, Spain; Hosp Univ Virgen de la Macarena, Sevilla, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Virgen de la Salud, Toledo, Spain; H. C. R. Noroeste de Murcia, Murcia, Spain
| | - C. Jara
- Hosp La Paz, Madrid, Spain; Hosp Univ Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hosp Juan Canalejo, A Coruña, Spain; Fundación Hosp de Alcorcón, Madrid, Spain; Hosp Univ Virgen de la Macarena, Sevilla, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Virgen de la Salud, Toledo, Spain; H. C. R. Noroeste de Murcia, Murcia, Spain
| | - J. A. Virizuela
- Hosp La Paz, Madrid, Spain; Hosp Univ Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hosp Juan Canalejo, A Coruña, Spain; Fundación Hosp de Alcorcón, Madrid, Spain; Hosp Univ Virgen de la Macarena, Sevilla, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Virgen de la Salud, Toledo, Spain; H. C. R. Noroeste de Murcia, Murcia, Spain
| | - A. Yubero
- Hosp La Paz, Madrid, Spain; Hosp Univ Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hosp Juan Canalejo, A Coruña, Spain; Fundación Hosp de Alcorcón, Madrid, Spain; Hosp Univ Virgen de la Macarena, Sevilla, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Virgen de la Salud, Toledo, Spain; H. C. R. Noroeste de Murcia, Murcia, Spain
| | - J. I. Chacón
- Hosp La Paz, Madrid, Spain; Hosp Univ Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hosp Juan Canalejo, A Coruña, Spain; Fundación Hosp de Alcorcón, Madrid, Spain; Hosp Univ Virgen de la Macarena, Sevilla, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Virgen de la Salud, Toledo, Spain; H. C. R. Noroeste de Murcia, Murcia, Spain
| | - J. Mira
- Hosp La Paz, Madrid, Spain; Hosp Univ Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hosp Juan Canalejo, A Coruña, Spain; Fundación Hosp de Alcorcón, Madrid, Spain; Hosp Univ Virgen de la Macarena, Sevilla, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Virgen de la Salud, Toledo, Spain; H. C. R. Noroeste de Murcia, Murcia, Spain
| | - M. González Barón
- Hosp La Paz, Madrid, Spain; Hosp Univ Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Hosp Juan Canalejo, A Coruña, Spain; Fundación Hosp de Alcorcón, Madrid, Spain; Hosp Univ Virgen de la Macarena, Sevilla, Spain; Hosp Obispo Polanco, Teruel, Spain; Hosp Virgen de la Salud, Toledo, Spain; H. C. R. Noroeste de Murcia, Murcia, Spain
| |
Collapse
|
16
|
López-Gómez L, Escudero P, Yubero A, Feliú J, Salud A, Galán A, Bolaños M, Vicent JM, Losa F, González-Barón M. XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. López-Gómez
- Hospital Virgen de la Salud, Toledo, Spain; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital La Paz, Madrid, Spain; Hospital Arnau de Villanova, Lleida, Spain; Hospital de Sagunto, Valencia, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital de la Creu Roja, Barcelona, Spain
| | - P. Escudero
- Hospital Virgen de la Salud, Toledo, Spain; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital La Paz, Madrid, Spain; Hospital Arnau de Villanova, Lleida, Spain; Hospital de Sagunto, Valencia, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital de la Creu Roja, Barcelona, Spain
| | - A. Yubero
- Hospital Virgen de la Salud, Toledo, Spain; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital La Paz, Madrid, Spain; Hospital Arnau de Villanova, Lleida, Spain; Hospital de Sagunto, Valencia, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital de la Creu Roja, Barcelona, Spain
| | - J. Feliú
- Hospital Virgen de la Salud, Toledo, Spain; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital La Paz, Madrid, Spain; Hospital Arnau de Villanova, Lleida, Spain; Hospital de Sagunto, Valencia, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital de la Creu Roja, Barcelona, Spain
| | - A. Salud
- Hospital Virgen de la Salud, Toledo, Spain; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital La Paz, Madrid, Spain; Hospital Arnau de Villanova, Lleida, Spain; Hospital de Sagunto, Valencia, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital de la Creu Roja, Barcelona, Spain
| | - A. Galán
- Hospital Virgen de la Salud, Toledo, Spain; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital La Paz, Madrid, Spain; Hospital Arnau de Villanova, Lleida, Spain; Hospital de Sagunto, Valencia, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital de la Creu Roja, Barcelona, Spain
| | - M. Bolaños
- Hospital Virgen de la Salud, Toledo, Spain; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital La Paz, Madrid, Spain; Hospital Arnau de Villanova, Lleida, Spain; Hospital de Sagunto, Valencia, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital de la Creu Roja, Barcelona, Spain
| | - J. M. Vicent
- Hospital Virgen de la Salud, Toledo, Spain; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital La Paz, Madrid, Spain; Hospital Arnau de Villanova, Lleida, Spain; Hospital de Sagunto, Valencia, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital de la Creu Roja, Barcelona, Spain
| | - F. Losa
- Hospital Virgen de la Salud, Toledo, Spain; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital La Paz, Madrid, Spain; Hospital Arnau de Villanova, Lleida, Spain; Hospital de Sagunto, Valencia, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital de la Creu Roja, Barcelona, Spain
| | - M. González-Barón
- Hospital Virgen de la Salud, Toledo, Spain; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital La Paz, Madrid, Spain; Hospital Arnau de Villanova, Lleida, Spain; Hospital de Sagunto, Valencia, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital de la Creu Roja, Barcelona, Spain
| |
Collapse
|
17
|
Feliú J, Escudero P, Losa F, Bolaños M, Vicent JM, Yubero A, Sanz-Lacalle J, López R, Dorta J, González-Barón M. A phase II study of capecitabine (X) in elderly patients (p) as 1st line treatment for patients (pts) with advanced or metastatic colorectal cancer (MCRC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3567] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. Feliú
- Hospital La Paz, Madrid, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital de la Cruz Roja, Barcelona, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Clínico de Santiago de Compostela, A Coruña, Spain; Hospital Virgen de la Candelaria, Tenerife, Spain
| | - P. Escudero
- Hospital La Paz, Madrid, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital de la Cruz Roja, Barcelona, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Clínico de Santiago de Compostela, A Coruña, Spain; Hospital Virgen de la Candelaria, Tenerife, Spain
| | - F. Losa
- Hospital La Paz, Madrid, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital de la Cruz Roja, Barcelona, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Clínico de Santiago de Compostela, A Coruña, Spain; Hospital Virgen de la Candelaria, Tenerife, Spain
| | - M. Bolaños
- Hospital La Paz, Madrid, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital de la Cruz Roja, Barcelona, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Clínico de Santiago de Compostela, A Coruña, Spain; Hospital Virgen de la Candelaria, Tenerife, Spain
| | - J. M. Vicent
- Hospital La Paz, Madrid, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital de la Cruz Roja, Barcelona, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Clínico de Santiago de Compostela, A Coruña, Spain; Hospital Virgen de la Candelaria, Tenerife, Spain
| | - A. Yubero
- Hospital La Paz, Madrid, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital de la Cruz Roja, Barcelona, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Clínico de Santiago de Compostela, A Coruña, Spain; Hospital Virgen de la Candelaria, Tenerife, Spain
| | - J. Sanz-Lacalle
- Hospital La Paz, Madrid, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital de la Cruz Roja, Barcelona, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Clínico de Santiago de Compostela, A Coruña, Spain; Hospital Virgen de la Candelaria, Tenerife, Spain
| | - R. López
- Hospital La Paz, Madrid, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital de la Cruz Roja, Barcelona, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Clínico de Santiago de Compostela, A Coruña, Spain; Hospital Virgen de la Candelaria, Tenerife, Spain
| | - J. Dorta
- Hospital La Paz, Madrid, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital de la Cruz Roja, Barcelona, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Clínico de Santiago de Compostela, A Coruña, Spain; Hospital Virgen de la Candelaria, Tenerife, Spain
| | - M. González-Barón
- Hospital La Paz, Madrid, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital de la Cruz Roja, Barcelona, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Clínico de Santiago de Compostela, A Coruña, Spain; Hospital Virgen de la Candelaria, Tenerife, Spain
| |
Collapse
|
18
|
Muñoz A, Salud A, Alonso V, Escudero P, Sanz JJ, Martín C, Rivera F, Yubero A, García-Girón C, López-Vivanco G. Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (LA) or metastatic colorectal cancer (MCRC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3610] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Muñoz
- Hospital de Cruces, Barakaldo, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital San Jorge, Huesca, Spain; Hospital Espíritu Santo, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital General Yagüe, Burgos, Spain
| | - A. Salud
- Hospital de Cruces, Barakaldo, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital San Jorge, Huesca, Spain; Hospital Espíritu Santo, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital General Yagüe, Burgos, Spain
| | - V. Alonso
- Hospital de Cruces, Barakaldo, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital San Jorge, Huesca, Spain; Hospital Espíritu Santo, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital General Yagüe, Burgos, Spain
| | - P. Escudero
- Hospital de Cruces, Barakaldo, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital San Jorge, Huesca, Spain; Hospital Espíritu Santo, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital General Yagüe, Burgos, Spain
| | - J. J. Sanz
- Hospital de Cruces, Barakaldo, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital San Jorge, Huesca, Spain; Hospital Espíritu Santo, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital General Yagüe, Burgos, Spain
| | - C. Martín
- Hospital de Cruces, Barakaldo, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital San Jorge, Huesca, Spain; Hospital Espíritu Santo, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital General Yagüe, Burgos, Spain
| | - F. Rivera
- Hospital de Cruces, Barakaldo, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital San Jorge, Huesca, Spain; Hospital Espíritu Santo, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital General Yagüe, Burgos, Spain
| | - A. Yubero
- Hospital de Cruces, Barakaldo, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital San Jorge, Huesca, Spain; Hospital Espíritu Santo, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital General Yagüe, Burgos, Spain
| | - C. García-Girón
- Hospital de Cruces, Barakaldo, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital San Jorge, Huesca, Spain; Hospital Espíritu Santo, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital General Yagüe, Burgos, Spain
| | - G. López-Vivanco
- Hospital de Cruces, Barakaldo, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Hospital San Jorge, Huesca, Spain; Hospital Espíritu Santo, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital General Yagüe, Burgos, Spain
| |
Collapse
|
19
|
Feliu J, Escudero P, Losa F, Bolaños M, Vicent J, Yubero A, Sanz-Lacalle J, López R, López-Gómez L, González-Barón M. 263 A study of capecitabine in elderly patients as first line treatment in advanced or metastatic colorectal cancer. EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90296-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
20
|
García-Carbonero R, Mayordomo JI, Tornamira MV, López-Brea M, Rueda A, Guillem V, Arcediano A, Yubero A, Ribera F, Gómez C, Trés A, Pérez-Gracia JL, Lumbreras C, Hornedo J, Cortés-Funes H, Paz-Ares L. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001; 93:31-8. [PMID: 11136839 DOI: 10.1093/jnci/93.1.31] [Citation(s) in RCA: 132] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Granulocyte colony-stimulating factors (G-CSFs) have been shown to help prevent febrile neutropenia in certain subgroups of cancer patients undergoing chemotherapy, but their role in treating febrile neutropenia is controversial. The purpose of our study was to evaluate-in a prospective multicenter randomized clinical trial-the efficacy of adding G-CSF to broad-spectrum antibiotic treatment of patients with solid tumors and high-risk febrile neutropenia. METHODS A total of 210 patients with solid tumors treated with conventional-dose chemotherapy who presented with fever and grade IV neutropenia were considered to be eligible for the trial. They met at least one of the following high-risk criteria: profound neutropenia (absolute neutrophil count <100/mm(3)), short latency from previous chemotherapy cycle (<10 days), sepsis or clinically documented infection at presentation, severe comorbidity, performance status of 3-4 (Eastern Cooperative Oncology Group scale), or prior inpatient status. Eligible patients were randomly assigned to receive the antibiotics ceftazidime and amikacin, with or without G-CSF (5 microg/kg per day). The primary study end point was the duration of hospitalization. All P values were two-sided. RESULTS Patients randomly assigned to receive G-CSF had a significantly shorter duration of grade IV neutropenia (median, 2 days versus 3 days; P = 0.0004), antibiotic therapy (median, 5 days versus 6 days; P = 0.013), and hospital stay (median, 5 days versus 7 days; P = 0.015) than patients in the control arm. The incidence of serious medical complications not present at the initial clinical evaluation was 10% in the G-CSF group and 17% in the control group (P = 0.12), including five deaths in each study arm. The median cost of hospital stay and the median overall cost per patient admission were reduced by 17% (P = 0.01) and by 11% (P = 0.07), respectively, in the G-CSF arm compared with the control arm. CONCLUSIONS Adding G-CSF to antibiotic therapy shortens the duration of neutropenia, reduces the duration of antibiotic therapy and hospitalization, and decreases hospital costs in patients with high-risk febrile neutropenia.
Collapse
Affiliation(s)
- R García-Carbonero
- Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Garcia-Carbonero R, Mayordomo J, Tornamira M, Lopez-Brea M, Rueda A, Guillem V, Yubero A, Rivera F, Cortes-Funes H, Paz-Ares L. Randomized comparison of broad spectrum antibiotics with or without filgrastim in the treatment of patients with high-risk fever and grade IV neutropenia. Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81877-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
22
|
Iñiguez C, Larrodé P, Mayordomo JI, González P, Adelantado S, Yubero A, Trés A, Morales F. Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel. Neurology 1998; 51:868-70. [PMID: 9748043 DOI: 10.1212/wnl.51.3.868] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Peripheral neuropathy (PN) is the main side effect with cycles of paclitaxel at standard doses (175 mg/m2 for 21 days). Administration of a single high-dose paclitaxel (HDP) is a novel approach for the treatment of cancer. We have prospectively measured neurotoxicity induced by HDP during a phase I trial. Nineteen patients were treated with escalating doses of paclitaxel by 24-hour infusion. In our study, PN induced by HDP was moderate, reversible, and not dose limiting. Severe PN was seen in patients who had received previous neurotoxic chemotherapy, and caution on the administration of HDP in this setting is warranted.
Collapse
Affiliation(s)
- C Iñiguez
- Department of Neurology, Hospital Clínico Universitario, Zaragoza, Spain
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Yubero A, Isla D, Mayordomo J, Cajal R, Alonso M, Bueso P, Herráez J, Escudero P, Moreno J, Tres A. Incidence of delayed infections after high-dose chemotherapy with peripheral blood stem cell support. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)84857-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
24
|
Alonso M, Isla D, Mayordomo J, Cajal R, Yubero A, Herráez J, Bueso P, Sáenz A, Palomera L, Tres A. Correlation between the number of CD34+ cells reinfused and complications and mortality of high-dose chemotherapy with stem cell support. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)84843-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Herráez J, Yubero A, Palomera L, Moreno J, Mayordomo J, Cajal R, Alonso M, Bueso P, Escudero P, Tres A. Number of CD34+cells infused and duration of aplasia after high-close chemotherapy. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)84849-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
26
|
Isla D, Astier P, Mayordomo J, Alonso M, Cajal R, Yubero A, Sáenz A, Escudero P, Abad A, Tres A. Economic costs of high-close chemotherapy with peripheral blood stem cell rescue. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)84867-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
27
|
Bueso P, Isla D, Mayordomo J, Alonso M, Herráez J, Cajal A, Yubero A, Escudero P, Sáenz A, Tres A. Long-term results of chemotherapy in advanced thyroid carcinoma. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)85547-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Yubero A, Majordomo J, Isla D, Cajal R, Iñíguez C, Larrodé P, Herráez J, Escudero P, Sáenz A, Tres A. Dose escalation of paclitaxel in combination with cyclophosphamide, thiotepa and carboplatin with stem cell rescue. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)84851-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
29
|
Alonso V, Florian J, Alonso M, Cajal R, Yubero A, Isla M, Escudero P, Saenz A, Mayordomo J, Tres A. 75 A pilot study of adjuvant postoperative chemohormonal therapy with 5-fluorouracil, doxorubicin, cyclophosphamide, vindesine and tamoxifen for resectable breast cancer. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)95327-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|